Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 144.86

+0.5%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (728)	5/24/2001 4:52:37 PM
From: Icebrg	Read Replies (1) of 1834

"RESEARCH ALERT-Four drug cos started as buy 5/24/2001 12:00:00 PM NEW YORK, May 24 (Reuters) - UBS Warburg analyst Andrew Gitkin started coverage of drug companies Cephalon Inc. (CEPH) , Guilford Pharmaceuticals Inc. (GLFD) , Neurocrine Biosciences Inc. (NBIX) and Cell Therapeutics Inc. (CTIC) with buy ratings on Thursday. ---snip--- Neurocrine's buy rating "is based on substantial revenue and earnings growth expected from the company's primary products," Gitkin said." ---snip--- The price target seems to be 46 USD, which would have looked great a couple of weeks ago, but feels somewhat yawny today. Bad luck for Mr. Gitkin. On the other hand, if UBS Warburg are serious about this, they have a tremendous placing power. Ice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next